Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease
Memory loss or dementia is a progressive disorder, and one of its common forms is Alzheimer’s disease (AD), effecting mostly middle aged and older adults. In the present study, we developed Rivastigmine (RIV) nanoparticles using poly(lactic-co-glycolic acid) (RIV-loaded PLGA NPs) and polyvinyl alcoh...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-05-01
|
| Series: | Saudi Pharmaceutical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016424000987 |
| _version_ | 1797235630152876032 |
|---|---|
| author | Faisal Imam Sayantan Mukhopadhyay Preeti Kothiyal Samiyah Alshehri Khalid Saad Alharbi Muhammad Afzal Muzaffar Iqbal Mohammad Rashid Khan Md. Khalid Anwer Abdulrazaq Ahmed Hattab Alanazi Ali Ghanem Alqahtani Mohammed Abdullah Alhamamah |
| author_facet | Faisal Imam Sayantan Mukhopadhyay Preeti Kothiyal Samiyah Alshehri Khalid Saad Alharbi Muhammad Afzal Muzaffar Iqbal Mohammad Rashid Khan Md. Khalid Anwer Abdulrazaq Ahmed Hattab Alanazi Ali Ghanem Alqahtani Mohammed Abdullah Alhamamah |
| author_sort | Faisal Imam |
| collection | DOAJ |
| description | Memory loss or dementia is a progressive disorder, and one of its common forms is Alzheimer’s disease (AD), effecting mostly middle aged and older adults. In the present study, we developed Rivastigmine (RIV) nanoparticles using poly(lactic-co-glycolic acid) (RIV-loaded PLGA NPs) and polyvinyl alcohol (PVA). The prepared RIV-PLGA nanoparticles was evaluated for the management of Alzheimer's disease (AD). The nanoparticles were prepared by the slightly modified nano-precipitation technique. The developed formulations were evaluated for particle size, zeta potential (ZP), polydispersibility index (PDI) and surface morphology and drug content. The experimental result revealed that prepared RIV-loaded PLGA NPs (F1) was optimized having particle size (61.2 ± 4.6 nm), PDI (0.292), ZP (−11.2 ± 1.2). SEM study confirms the prepared nanoparticles depicted non-aggregated as well smooth surface particles without any fracture. This formulation (F1) was further assessed for in vivo studies on animal model. A pharmacological screening on an animal model of Alzheimer's disease revealed that RIV-loaded PLGA NPs formulations treat CNS disorders like Alzheimer's effectively. In addition to that, an in-vivo brain cholinesterase estimation study found that, animals treated with optimized formulation significantly (p < 0.01) reduced brain cholinesterase activity when compared to scopolamine-treated animals. According to the above results, it can be concluded that RIV-loaded PLGA NPs are ideal carriers for delivering the drug at a specific target site in the brain, thus may treat Alzheimer's disease efficiently and improve patient compliance. |
| first_indexed | 2024-04-24T16:51:00Z |
| format | Article |
| id | doaj.art-c2d9694334234b878a82eeab4bfe2bcb |
| institution | Directory Open Access Journal |
| issn | 1319-0164 |
| language | English |
| last_indexed | 2024-04-24T16:51:00Z |
| publishDate | 2024-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj.art-c2d9694334234b878a82eeab4bfe2bcb2024-03-29T05:49:41ZengElsevierSaudi Pharmaceutical Journal1319-01642024-05-01325102048Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s diseaseFaisal Imam0Sayantan Mukhopadhyay1Preeti Kothiyal2Samiyah Alshehri3Khalid Saad Alharbi4Muhammad Afzal5Muzaffar Iqbal6Mohammad Rashid Khan7Md. Khalid Anwer8Abdulrazaq Ahmed Hattab Alanazi9Ali Ghanem Alqahtani10Mohammed Abdullah Alhamamah11Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; Corresponding author at: Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box: 2457, Riyadh 11451, Saudi Arabia.College of Pharmacy, Shivalik Campus, Dehradun, Uttarakhand, IndiaSchool of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Navagaon, Maduwala, Dehradun 248007, Uttarakhand, IndiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Al-Qassim, Saudi ArabiaDepartment of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, P.O. Box 6231, Jeddah 21442, Saudi ArabiaDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; Security Forces Specialized Polyclinics in East Riyadh, General Department of Medical Services, MOI, P. O. Box 7838, Riyadh 11134, Saudi ArabiaDepartment of Pharmaceutical Care, Assir Health, Ministry of Health, Abha 11176, Saudi ArabiaDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaMemory loss or dementia is a progressive disorder, and one of its common forms is Alzheimer’s disease (AD), effecting mostly middle aged and older adults. In the present study, we developed Rivastigmine (RIV) nanoparticles using poly(lactic-co-glycolic acid) (RIV-loaded PLGA NPs) and polyvinyl alcohol (PVA). The prepared RIV-PLGA nanoparticles was evaluated for the management of Alzheimer's disease (AD). The nanoparticles were prepared by the slightly modified nano-precipitation technique. The developed formulations were evaluated for particle size, zeta potential (ZP), polydispersibility index (PDI) and surface morphology and drug content. The experimental result revealed that prepared RIV-loaded PLGA NPs (F1) was optimized having particle size (61.2 ± 4.6 nm), PDI (0.292), ZP (−11.2 ± 1.2). SEM study confirms the prepared nanoparticles depicted non-aggregated as well smooth surface particles without any fracture. This formulation (F1) was further assessed for in vivo studies on animal model. A pharmacological screening on an animal model of Alzheimer's disease revealed that RIV-loaded PLGA NPs formulations treat CNS disorders like Alzheimer's effectively. In addition to that, an in-vivo brain cholinesterase estimation study found that, animals treated with optimized formulation significantly (p < 0.01) reduced brain cholinesterase activity when compared to scopolamine-treated animals. According to the above results, it can be concluded that RIV-loaded PLGA NPs are ideal carriers for delivering the drug at a specific target site in the brain, thus may treat Alzheimer's disease efficiently and improve patient compliance.http://www.sciencedirect.com/science/article/pii/S1319016424000987NanoparticlePLGANanoprecipitationAlzheimer’s diseaseCholinesterase |
| spellingShingle | Faisal Imam Sayantan Mukhopadhyay Preeti Kothiyal Samiyah Alshehri Khalid Saad Alharbi Muhammad Afzal Muzaffar Iqbal Mohammad Rashid Khan Md. Khalid Anwer Abdulrazaq Ahmed Hattab Alanazi Ali Ghanem Alqahtani Mohammed Abdullah Alhamamah Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease Saudi Pharmaceutical Journal Nanoparticle PLGA Nanoprecipitation Alzheimer’s disease Cholinesterase |
| title | Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease |
| title_full | Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease |
| title_fullStr | Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease |
| title_full_unstemmed | Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease |
| title_short | Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease |
| title_sort | formulation and characterization of polymeric nanoparticle of rivastigmine for effective management of alzheimer s disease |
| topic | Nanoparticle PLGA Nanoprecipitation Alzheimer’s disease Cholinesterase |
| url | http://www.sciencedirect.com/science/article/pii/S1319016424000987 |
| work_keys_str_mv | AT faisalimam formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT sayantanmukhopadhyay formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT preetikothiyal formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT samiyahalshehri formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT khalidsaadalharbi formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT muhammadafzal formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT muzaffariqbal formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT mohammadrashidkhan formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT mdkhalidanwer formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT abdulrazaqahmedhattabalanazi formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT alighanemalqahtani formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease AT mohammedabdullahalhamamah formulationandcharacterizationofpolymericnanoparticleofrivastigmineforeffectivemanagementofalzheimersdisease |